Recombinant Human Breast Carcinoma-Amplified Sequence 2/BCAS2 is produced by our E. coli expression system. The target protein is expressed with sequence (Ala2-Phe225) of Human BCAS2 fused with a 6His tag at the C-terminus.
Pureté
> 95 % as determined by reducing SDS-PAGE.
Stérilité
0.2 μm filtered
niveau d'endotoxine
Less than 0.1 ng/μg (1 IEU/μg) as determined by LAL test
It is not recommended to reconstitute to a concentration less than 100 μg/mL. Dissolve the lyophilized protein in ddH2O. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Buffer
Lyophilized from a 0.2 μm filtered solution of 20 mM TrisHCl, 200 mM NaCl, 2 mM DTT, pH 8.0.
Agent conservateur
Dithiothreitol (DTT)
Précaution d'utilisation
This product contains Dithiothreitol (DTT): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Conseil sur la manipulation
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
Stock
4 °C/-20 °C/-80 °C
Stockage commentaire
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Breast Carcinoma-Amplified Sequence 2 (BCAS2) is a member of the SPF27 family. BCAS2 is a nuclear protein and widely expressed in many rtissues. BCAS2 is identified as being overexpressed in various breast cancer cell lines. BCAS2 is a component of the spliceosome, taking part in the removal of introns from mRNA precursors. BCAS2 interacts with estrogen receptor alpha and beta, thyroid hormone receptor beta, peroxisome proliferator-activated receptor gamma. BCAS2 functions as an ER co-activator and is capable of enhancing ER-mediated transcription. Alternative Names: Pre-mRNA-Splicing Factor SPF27, Breast Carcinoma-Amplified Sequence 2, DNA Amplified in Mammary Carcinoma 1 Protein, Spliceosome-Associated Protein SPF 27, BCAS2, DAM1